Work

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Year: 2017

Type: article

Source: Nature

DOI: 10.1038/nature23291

Authors: Zhan Yao, Rona Yaeger, Vanessa S. Rodrik-Outmezguine, Anthony Tao, Neilawattie M. Torres, Matthew T. Chang, Matthias Drosten, Huiyong Zhao, Fabiola Cecchi, Todd Hembrough, Judith Michels, Hervé Baumert, Linde Miles, Naomi M. Campbell, Elisa de Stanchina, David B. Solit, Mariano Barbacid, Barry S. Taylor, Neal Rosen

Institutions: Memorial Sloan Kettering Cancer Center, New York University, University of California, San Francisco, Spanish National Cancer Research Centre, NantOmics LLC (United States), Université Paris-Sud, Institut Gustave Roussy, Hôpital Paris Saint-Joseph, Johns Hopkins University

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences

Awards: Understanding Long Tail Driver Mutations in Cancer, G1380091450, Developing therapeutic strategies for ERK-dependent tumors, G2684890037, Studies on oncoprotein-induced feedback: Basic and therapeutic implications, G6445245891, Pharmaceutical Sciences and Pharmacogenomics, G9000079197, Cancer Center Support Grant

OpenAlex ID: W2739964468

FWCI: 18.34

Cites: 18

Cited by: 560

Related to: 10